Interventions of Interest
For questions please contact [email protected].
- synthetic psilocybin (COMPASS Pathways)
Depression: Treatment-Resistant
An assessment of synthetic psilocybin
Public Meeting
May 2027
Assessment Status
Ongoing
Upcoming Milestone
Draft Scoping DocumentView
Main Review
May 20, 2027
New England CEPAC
The New England CEPAC 2027 public meeting on synthetic psilocybin for treatment-resistant depression.
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- Compass Pathways
- Definium Therapeutics
- Depression and Bipolar Support Alliance (DBSA)
- Letters to Strangers
- Mental Health America
- National Alliance on Mental Illness (NAMI)
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Public Comment Period
See Full Timeline
10/21/2026 - 11/10/2026
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
Post-Traumatic Stress Disorder
May 2024Depression: Treatment-Resistant
May 2019Depression: Treatment-Resistant
Dec 2011
10/21/2026 - 11/10/2026
Public Comments on Draft Scoping Document
11/18/2026
Revised Scoping Document
11/25/2026
Research Protocol
01/22/2027
Model Analysis Plan
05/05/2027
Evidence Report
05/20/2027
Evidence Presentation
06/18/2027
Public Comments
OpenView
Closed